Influence of APOE genotype and the presence of Alzheimer's pathology on synaptic membrane lipids of human brains

Journal of Neuroscience Research

Volumn 92, Issue 5, 2014, Pages 641-650

  Oikawa, Naoto ^a   Hatsuta, Hiroyuki ^b   Murayama, Shigeo ^b   Suzuki, Akemi ^c   Yanagisawa, Katsuhiko ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cholesterol; Ganglioside; Microdomain; Synaptic plasma membrane

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; GANGLIOSIDE; GANGLIOSIDE GD1; GANGLIOSIDE GM1; GANGLIOSIDE GT1; MEMBRANE LIPID; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN SYNAPTOSOME; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; SYNAPTIC MEMBRANE; VERY ELDERLY;

ALZHEIMER'S DISEASE; CHOLESTEROL; GANGLIOSIDE; MICRODOMAIN; SYNAPTIC PLASMA MEMBRANE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL; FEMALE; GANGLIOSIDES; GENOTYPE; HUMANS; LIPIDS; MALE; SYNAPTIC MEMBRANES; SYNAPTOSOMES;

EID: 84895920241     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23341     Document Type: Article

References (50)

1. Adachi T, Saito Y, Hatsuta H, Funabe S, Tokumaru AM, Ishii K, Arai T, Sawabe M, Kanemaru K, Miyashita A, Kuwano R, Nakashima K, Murayama S. 2010. Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol 69:737-744.
2. Ariga T, McDonald MP, Yu RK. 2008. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review. J Lipid Res 49:1157-1175.
3. Bandaru VV, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K, Haughey NJ. 2009. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 30:591-599.
4. Benjamin R, Leake A, McArthur FK, Ince PG, Candy JM, Edwardson JA, Morris CM, Bjertness E. 1994. Protective effect of apoE epsilon 2 in Alzheimer's disease. Lancet 344:473.
5. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259.
6. Bugiani O, Giaccone G, Verga L, Pollo B, Ghetti B, Frangione B, Tagliavini F. 1990. Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neurosci Lett 119:56-59.
7. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. 2000. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157:277-286.
8. Cossec JC, Marquer C, Panchal M, Lazar AN, Duyckaerts C, Potier MC. 2010a. Cholesterol changes in Alzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes. Biochim Biophys Acta 1801:839-845.
9. Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J, Duyckaerts C, Lenkei Z, Potier MC. 2010b. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta 1801:846-852.
10. Cotman CW, Matthews DA. 1971. Synaptic plasma membranes from rat brain synaptosomes: isolation and partial characterization. Biochim Biophys Acta 249:380-394.
11. Crino PB, Ullman MD, Vogt BA, Bird ED, Volicer L. 1989. Brain gangliosides in dementia of the Alzheimer type. Arch Neurol 46:398-401.
12. Di Paolo G, Kim TW. 2011. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12:284-296.
13. Di Scala C, Troadec JD, Lelièvre C, Garmy N, Fantini J, Chahinian H. 2013. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide. J Neurochem (in press).
14. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. 2013. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73:104-119.
15. Fantini J, Yahi N, Garmy N. 2013. Cholesterol accelerates the binding of Alzheimer's β-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation. Front Physiol 4:120.
16. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
17. Fontaine RN, Harris RA, Schroeder F. 1980. Aminophospholipid asymmetry in murine synaptosomal plasma membrane. J Neurochem 34:269-277.
18. Gorbenko GP, Kinnunen PK. 2006. The role of lipid-protein interactions in amyloid-type protein fibril formation. Chem Phys Lipids 141:72-82.
19. Gylys KH, Fein JA, Yang F, Miller CA, Cole GM. 2007. Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol Aging 28:8-17.
20. Hayashi H, Igbavboa U, Hamanaka H, Kobayashi M, Fujita SC, Wood WG, Yanagisawa K. 2002. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport 13:383-386.
21. Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K. 2004. A seed for Alzheimer amyloid in the brain. J Neurosci 24:4894-4902.
22. Hicks DA, Nalivaeva NN, Turner AJ. 2012. Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling. Front Physiol 3:189.
23. Holtzman DM, Herz J, Bu G. 2012. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspect Med 2:a006312.
24. Igbavboa U, Avdulov NA, Schroeder F, Wood WG. 1996. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem 66:1717-1725.
25. Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. 2001. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276:24985-24990.
26. Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovič C, Lauc G. 1991. Human brain gangliosides in development, aging and disease. Int J Dev Biol 35:289-295.
27. Lichtenberg D, Goñi FM, Heerklotz H. 2005. Detergent-resistant membranes should not be identified with membrane rafts. Trends Biochem Sci 30:430-436.
28. Lingwood D, Simons K. 2007. Detergent resistance as a tool in membrane research. Nat Protoc 2:2159-2165.
29. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. 1997. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 48:515-519.
30. Liu CC, Kanekiyo T, Xu H, Bu G. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106-118.
31. Matsuzaki K, Kato K, Yanagisawa K. 2010. Abeta polymerization through interaction with membrane gangliosides. Biochim Biophys Acta 1801:868-877.
32. Michikawa M, Fan QW, Isobe I, Yanagisawa K. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74:1008-1016.
33. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Månsson JE, Fredman P. 2005. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 92:171-182.
34. Nagafuku M, Okuyama K, Onimaru Y, Suzuki A, Odagiri Y, Yamashita T, Iwasaki K, Fujiwara M, Takayanagi M, Ohno I, Inokuchi J. 2012. CD4 and CD8 T cells require different membrane gangliosides for activation. Proc Natl Acad Sci U S A 109:E336-E342.
35. Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD. 1995. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69:757-761.
36. Oikawa N, Goto M, Ikeda K, Taguchi R, Yanagisawa K. 2012. The γ-secretase inhibitor DAPT increases the levels of gangliosides at neuritic terminals of differentiating PC12 cells. Neurosci Lett 525:49-53.
37. Op Den Velde W, Hooghwinkel GJ. 1975. The brain ganglioside pattern in presenile and senile dementia. J Am Geriatr Soc 23:301-303.
38. Oyama F, Shimada H, Oyama R, Ihara Y. 1995. Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population. Brain Res Mol Brain Res 29:92-98.
39. Persaud-Sawin DA, Lightcap S, Harry GJ. 2009. Isolation of rafts from mouse brain tissue by a detergent-free method. J Lipid Res 50:759-767.
40. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinistö L, Halonen P, Kontula K. 1995. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333:1242-1247.
41. Probst A, Langui D, Ipsen S, Robakis N, Ulrich J. 1991. Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathol 83:21-29.
42. Rapp A, Gmeiner B, Hüttinger M. 2006. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88:473-483.
43. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. 2009. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106:6820-6825.
44. Rushworth JV, Hooper NM. 2010. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis 2011:603052.
45. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90:9649-9653.
46. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. 2004. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62:1977-1983.
47. Yamamoto N, Igbabvoa U, Shimada Y, Ohno-Iwashita Y, Kobayashi M, Wood WG, Fujita SC, Yanagisawa K. 2004. Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett 569:135-139.
48. Yamamoto N, Matsubara T, Sato T, Yanagisawa K. 2008. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim Biophys Acta 1778:2717-2726.
49. Yanagisawa K. 2007. Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta 1768:1943-1951.
50. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. 1995. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med 1:1062-1066.